Navigation Links
Newbridge Securities Corporation Forms BioVentures Division
Date:2/17/2009

Newbridge Expands its Presence in the Biotech Industry

FT. LAUDERDALE, Fla., Feb. 17 /PRNewswire/ -- Newbridge Securities Corporation ("Newbridge"), a full-service securities broker-dealer and investment bank, is proud to announce the formation of the Newbridge BioVentures Division ("NBV"). NBV is dedicated to providing investment banking services for the biotech industry and related investment opportunities for institutional and sophisticated individual investors.

We are pleased to announce Christopher Carra as the Managing Director of NBV. Mr. Carra has been a registered representative in the securities industry for over 16 years, primarily focused in the biotech sector. Mr. Carra has been involved in several private placements and initial public offerings for biotech companies, and is a founding member of NBV. Prior to joining Newbridge in 2005, Mr. Carra worked at several private-client focused firms, most recently Oppenheimer & Co., where he worked from 2000-2005 as a senior vice president.

Please visit the BioVentures website; it can be accessed through www.newbridgesecurities.com or www.investbiopharma.com.

"We are extremely excited to add NBV as a focus to our already diversified suite of businesses," said Guy S. Amico, Newbridge's president. "In addition, having powerful advisors, such as Dr. David Sherris, Ph.D., on the Scientific Advisory board will lend top-level credibility and research to enhance our success rate for our Institutional and Private Client Group clients."

About Newbridge

Newbridge Securities Corporation provides full service securities brokerage and investment banking services to a broad based group of individuals and corporate clients. Comprised of a committed and experienced team of financial service professionals, we seek to empower our clients to build and preserve wealth by providing superior financial services and products.

For more information on NBV, contact Christopher Cara at 561.391.1220 (email at ccara@newbridgesecurities.com) or visit our website at www.newbridgesecurities.com.


'/>"/>
SOURCE Newbridge Securities Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission
2. deCODE Sells Auction Rate Securities
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
5. Isolagen to Present at the JMP Securities Healthcare Focus Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
7. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
8. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
9. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
10. NxStage Medical to Present at JMP Securities Healthcare Focus Conference
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... ... ACEA Biosciences, a pioneer in cell analysis instrumentation and the development of ... as the new Vice President of Global Clinical Development. With more than 15 ... will now team with Dr. Li Xu, Chief Medical Officer, and Dr. Xiao Xu, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... science and biotechnology companies today announced it named Joan Siefert Rose as ... out of Durham, NC and will begin work immediately. , Rose most recently ...
(Date:2/28/2017)... , Feb. 28, 2017 Sangamo ... genome editing, today reported its fourth quarter and ... "Early this year we rebranded our ... clinical development of genomic therapies using our industry ... gene regulation and cell therapy," said Sandy ...
(Date:2/27/2017)... 2017 A Europe-wide survey of institutes conducted ... animals in their research treat them with due care. The survey ... analysis of the results indicates that there is a strong commitment ... into practice the principles of the 3Rs (Refine, Reduce, Replace)  ... What are the ...
Breaking Biology Technology:
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):